【普门科技：H100Plus血红蛋白检测系统获美国FDA准入】普门科技公告称，公司H100Plus血红蛋白检测系统获得美国FDA 510准入，上市编号为K260468，监管类别为Class II，获批时间为2026年10月2日，预期用途为体外定量检测人全血中糖化血红蛋白含量，可辅助糖尿病诊断。该产品获得准入表明其符合美国FDA相关要求，具备美国市场准入资格，有利于提升公司海外市场综合竞争力，对国际业务发展具有积极作用。其实际销售情况受多方面因素影响，目前尚无法预测对未来业绩的具体影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.